目的探讨母牛分枝杆菌菌苗在耐多药肺结核患者免疫治疗中的应用价值。方法选取2012年6月至2013年6月营口市第三人民医院收治的耐多药肺结核患者68例为研究对象,按随机数字表法分为观察组与对照组,每组34例。观察组给予患者母牛分枝杆菌菌苗+化疗,对照组患者仅给予化疗,比较两组患者的治疗效果。结果观察组总有效率为94.1%,高于对照组的76.5%,差异有统计学意义(P<0.05);观察组治疗2、4、6个月后,痰菌转阴率、病灶吸收率及空洞闭合率均高于对照组,差异均有统计学意义(均P<0.05)。结论母牛分枝杆菌菌苗在耐多药肺结核免疫治疗中的应用效果显著,可有效提高化疗效果。 Objective To investigate the value of mycobacterium vaccae vaccine in the immunotherapy of multidrug-resistant pulmonary tuberculosis patients. Methods 68 patients with MDR-TB from June 2012 to June 2013 in Yingkou Third People’s Hospital were enrolled in this study. According to the random number table, they were divided into observation group and control group with 34 cases in each group. Patients in the observation group were treated with Mycobacterium vaccae vaccine + chemotherapy, while patients in the control group were given only chemotherapy, and the treatment effect was compared between the two groups. Results The total effective rate in the observation group was 94.1%, which was higher than that in the control group (76.5%), the difference was statistically significant (P <0.05). After 2, 4, and 6 months of treatment, the sputum negative conversion rate, And cavity closure rate were higher than the control group, the difference was statistically significant (P <0.05). Conclusion The application of Mycobacterium vaccae vaccine in MDR-TB immunotherapy is significant and can effectively improve the efficacy of chemotherapy.